The Abingworth Clinical Co-Development Fund 2 (ACCD 2) has exceeded its target of $350m and closed at the hard cap.

ACCD 2 will be used to advance late-stage clinical programmes from pharmaceutical and biotechnology companies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company plans to invest in late-stage product financing. The fund will also invest via its co-development portfolio companies Avillion in the UK and SFJ Pharmaceuticals in the US.

These two companies fund and support implementation of clinical trials, utilising their operational proficiency to expedite trials and boost their quality. They are subject to clinical and regulatory risk, as well as get pre-negotiated returns when a drug receives approval.

Recently, the company raised $465m for the Abingworth Bioventures 8 (ABV 8) fund as well as more than $1bn to invest in life science firms in the US, UK and Continental Europe which develop treatments to possibly enhance human health.

Abingworth initiated the clinical co-development approach in 2009 by investing through its venture funds. In 2016, the Abingworth clinical co-development fund (ACCD 1) was unveiled.

So far, Abingworth had invested in 11 co-development deals with the help of Avillion and SFJ.

Of the seven completed investments, six provided pre-negotiated pay-outs to the fund while five lead to drug approvals by the US Food and Drug Administration.

Presently, the companies are collaborating with AstraZeneca, Apellis Pharmaceuticals, Nektar Therapeutics and PhaseBio Pharmaceuticals.

Abingworth managing partner Kurt von Emster said: “Our bespoke clinical co-development approach has succeeded as an alternative investment strategy since we pioneered the concept a decade ago, both in terms of generating returns for investors and gaining new product approvals.

“Our CCD programme enables biotech companies to avoid near-term equity dilution and enables resource-constrained pharma companies to pursue additional clinical projects.”

With the latest fund closing, James Cornwall, who worked with Nuvelution and Quintiles, has joined Abingworth as a partner. Cornwall will be responsible for business development related to clinical co-development deals.

Also, PPD chairman and CEO David Simmons will serve as senior advisor to the company.